Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285391027> ?p ?o ?g. }
- W4285391027 endingPage "971" @default.
- W4285391027 startingPage "960" @default.
- W4285391027 abstract "SARS-CoV-2 mRNA vaccination of healthy individuals is highly immunogenic and protective against severe COVID-19. However, there are limited data on how disease-modifying therapies (DMTs) alter SARS-CoV-2 mRNA vaccine immunogenicity in patients with autoimmune diseases.As part of a prospective cohort study, we investigated the induction, stability and boosting of vaccine-specific antibodies, B cells and T cells in patients with multiple sclerosis (MS) on different DMTs after homologous primary, secondary and booster SARS-CoV-2 mRNA vaccinations. Of 126 patients with MS analysed, 105 received either anti-CD20-based B cell depletion (aCD20-BCD), fingolimod, interferon-β, dimethyl fumarate, glatiramer acetate, teriflunomide or natalizumab, and 21 were untreated MS patients for comparison.In contrast to all other MS patients, and even after booster, most aCD20-BCD- and fingolimod-treated patients showed no to markedly reduced anti-S1 IgG, serum neutralising activity and a lack of receptor binding domain-specific and S2-specific B cells. Patients receiving fingolimod additionally lacked spike-reactive CD4+ T cell responses. The duration of fingolimod treatment, rather than peripheral blood B and T cell counts prior to vaccination, determined whether a humoral immune response was elicited.The lack of immunogenicity under long-term fingolimod treatment demonstrates that functional immune responses require not only immune cells themselves, but also access of these cells to the site of inoculation and their unimpeded movement. The absence of humoral and T cell responses suggests that fingolimod-treated patients with MS are at risk for severe SARS-CoV-2 infections despite booster vaccinations, which is highly relevant for clinical decision-making and adapted protective measures, particularly considering additional recently approved sphingosine-1-phosphate receptor antagonists for MS treatment." @default.
- W4285391027 created "2022-07-14" @default.
- W4285391027 creator A5002158875 @default.
- W4285391027 creator A5002488352 @default.
- W4285391027 creator A5007303691 @default.
- W4285391027 creator A5008720696 @default.
- W4285391027 creator A5017829481 @default.
- W4285391027 creator A5020775252 @default.
- W4285391027 creator A5026670142 @default.
- W4285391027 creator A5031245590 @default.
- W4285391027 creator A5037553994 @default.
- W4285391027 creator A5038659108 @default.
- W4285391027 creator A5040615109 @default.
- W4285391027 creator A5042572033 @default.
- W4285391027 creator A5049295729 @default.
- W4285391027 creator A5050076508 @default.
- W4285391027 creator A5053515753 @default.
- W4285391027 creator A5056294224 @default.
- W4285391027 creator A5060361341 @default.
- W4285391027 creator A5062886940 @default.
- W4285391027 creator A5063085323 @default.
- W4285391027 creator A5067769986 @default.
- W4285391027 creator A5072964815 @default.
- W4285391027 creator A5075692819 @default.
- W4285391027 creator A5086835391 @default.
- W4285391027 creator A5088512021 @default.
- W4285391027 creator A5088948702 @default.
- W4285391027 date "2022-07-14" @default.
- W4285391027 modified "2023-10-18" @default.
- W4285391027 title "SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod" @default.
- W4285391027 cites W1654241956 @default.
- W4285391027 cites W2001440348 @default.
- W4285391027 cites W2030439098 @default.
- W4285391027 cites W2036071939 @default.
- W4285391027 cites W2041397952 @default.
- W4285391027 cites W2061815509 @default.
- W4285391027 cites W2097728608 @default.
- W4285391027 cites W2155409930 @default.
- W4285391027 cites W2171241954 @default.
- W4285391027 cites W2769546943 @default.
- W4285391027 cites W2771951908 @default.
- W4285391027 cites W2791846933 @default.
- W4285391027 cites W2794305622 @default.
- W4285391027 cites W2885426794 @default.
- W4285391027 cites W3014067025 @default.
- W4285391027 cites W3022213434 @default.
- W4285391027 cites W3037709082 @default.
- W4285391027 cites W3041222256 @default.
- W4285391027 cites W3045971896 @default.
- W4285391027 cites W3080524815 @default.
- W4285391027 cites W3091214020 @default.
- W4285391027 cites W3094968263 @default.
- W4285391027 cites W3096867322 @default.
- W4285391027 cites W3110691890 @default.
- W4285391027 cites W3111613708 @default.
- W4285391027 cites W3115528239 @default.
- W4285391027 cites W3119465992 @default.
- W4285391027 cites W3120392574 @default.
- W4285391027 cites W3121831652 @default.
- W4285391027 cites W3132346899 @default.
- W4285391027 cites W3134238461 @default.
- W4285391027 cites W3158483423 @default.
- W4285391027 cites W3158831599 @default.
- W4285391027 cites W3161511556 @default.
- W4285391027 cites W3162400064 @default.
- W4285391027 cites W3162833512 @default.
- W4285391027 cites W3164720238 @default.
- W4285391027 cites W3165359464 @default.
- W4285391027 cites W3165514001 @default.
- W4285391027 cites W3166152977 @default.
- W4285391027 cites W3169673565 @default.
- W4285391027 cites W3175310506 @default.
- W4285391027 cites W3197781442 @default.
- W4285391027 cites W3199923482 @default.
- W4285391027 cites W3200136047 @default.
- W4285391027 cites W3203569618 @default.
- W4285391027 cites W3210401977 @default.
- W4285391027 cites W3212651223 @default.
- W4285391027 cites W3215557511 @default.
- W4285391027 cites W3215961325 @default.
- W4285391027 cites W4200133924 @default.
- W4285391027 cites W4200335640 @default.
- W4285391027 cites W4205483821 @default.
- W4285391027 cites W4206946147 @default.
- W4285391027 cites W4210825328 @default.
- W4285391027 cites W4220816065 @default.
- W4285391027 cites W4220825786 @default.
- W4285391027 cites W4224945195 @default.
- W4285391027 cites W4226187849 @default.
- W4285391027 doi "https://doi.org/10.1136/jnnp-2022-329395" @default.
- W4285391027 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35835468" @default.
- W4285391027 hasPublicationYear "2022" @default.
- W4285391027 type Work @default.
- W4285391027 citedByCount "17" @default.
- W4285391027 countsByYear W42853910272022 @default.
- W4285391027 countsByYear W42853910272023 @default.
- W4285391027 crossrefType "journal-article" @default.
- W4285391027 hasAuthorship W4285391027A5002158875 @default.